2016 American Transplant Congress
Utilization of Plasmapheresis and High Dose of Immunoglobulins in the Treatment of the High Level of De Novo Donor Specific Antibodies for the Successful Islet Allotransplantation.
Background.Development of donor specific antibodies (DSA) after islet transplantation has been a poor prognostic factor for graft survival, while no intervention is implemented. Here, we…2016 American Transplant Congress
Optimized Flow Cytometry Crossmatch with Increased Sensitivity and Specificity.
The flow cytometry crossmatch (FCXM) is the standard method to prevent hyperacute rejection after transplantation. Surprisingly, few technical improvements have been introduced to the FCXM…2016 American Transplant Congress
Selective Deletion of Notch2 on B Cells Abrogates Alloantibody Production in Fully MHC-Mismatched Cardiac and Skin Transplant Models.
Alloantibody-mediated injury remains a major challenge for the improvement of long-term graft survival and there is no effective therapy to prevent alloantibody generation post-transplant. The…2016 American Transplant Congress
Comparison of C4d Deposition in Renal Biopsies with Luminex-Based C3d Single Antigen Bead (SAB) Detection.
Recent interest in characterizing the complement-fixing ability of post-transplant donor specific alloantibodies (DSA) resulted in the enhancement of luminex solid phase alloantibody assays to determine…2016 American Transplant Congress
Intravenous Immunoglobulins Failed to Prevent Acute Antibody-Mediated Rejection in Kidney Transplant Recipients with De Novo DSA within the First Year After Transplant.
BackgroundAround 25% of kidney transplant recipients develop de novo anti-HLA donor specific antibodies (DSA). Most of them are detected within the first year after transplant.…2016 American Transplant Congress
Breadth of HLA-Specific B Cell Reactivity and Frequency Assessed by a Novel Multiplex Bead Based Assay Predicts and Correlates with Rejection in Kidney Transplant Recipients.
Northwestern University, Chicago.
Introduction: Recipients with broad sensitization to HLA defined by a high percentage of Panel Reactive Antibodies (PRA) are at higher immunologic risk for poor graft…2016 American Transplant Congress
CTLA4 Negatively Regulates Donor-Reactive CXCR5+PD1+ T Follicular Helper Cell Responses Following Transplantation.
1Emory Transplant Center, Atlanta; 2Bristol-Myers Squibb, Princeton.
Costimulation blockade of the CD28 pathway in the form of CTLA4Ig is known to attenuate T cell dependent antibody responses. T follicular helper (Tfh) cells…2016 American Transplant Congress
Predicting the Timing of Graft Failure in De Novo DSA Positive Patients.
The risk of graft failure after de novo DSA (dnDSA) is not always immediate. To make more informed therapeutic decisions in dnDSA+ patients, we need…2016 American Transplant Congress
Measuring Efficacy of Antibody Removal Therapies: Back to Titers.
1Northwestern University, Chicago; 2Hopital Saint-Louis, Paris, France; 3UCLA, LA.
The need for reliable tools to predict likelihood of HLA-antibody responses to treatment and to monitor efficacy of antibody removal therapies manifests itself on two…2016 American Transplant Congress
Do All cPRA 100% Candidates Have Equal Access to Organ Allocation?
Renal transplant candidates with cPRA values of 98%, 99%, and 100% received local, regional, and national priority, respectively, for deceased donor kidneys with the new…
- « Previous Page
- 1
- …
- 29
- 30
- 31
- 32
- 33
- …
- 40
- Next Page »